Acute GVHD (aGVHD) is one of the major problems after allogeneic BMT. The diagnosis of aGVHD is difficult to establish, relying mainly on clinical evaluations and symptoms of aGVHD, often resembling those of organ toxicity, infection or drug rash. In 21 patients after BMT several serum cytokine levels (soluble interleukin-2 receptor (sIL-2R), sTNF-R, SCF, IL-6, IL-8, G-SCF and ICAM-1) were determined in order to evaluate their value as an indicator for aGVHD. The maximum levels of sIL-2R (and none of the other evaluated cytokines) correlated significantly (r = 0.8, P = 0.008) with the severity of aGVHD. We also found a significant correlation between the day of engraftment (neutrophil count Ͼ0.5 × 10 9 /l) and the severity of aGVHD (r = 0.5, P = 0.03): engraftment was earlier in patients without aGVHD (median of day 11) than in those with aGVHD (median of day 18). No correlation between sIL-2R and fever or organ toxicity could be found. Our data suggest that the sIL-2R level might be an indicator for aGVHD, reflecting the severity of the disease. In patients with late engraftment the risk of aGVHD seems to be increased, therefore these patients especially should be monitored closely, possibly using sIL-2R levels.
role in activating T cells. 3, 4 Once activated, T cells express the interleukin-2 receptor (IL-2R), consisting of at least three subunits (␣, ␤ and ␥ c ) on their membrane. 5, 6 Current understanding of the receptor is presented by Minami and coworkers. 6 Interleukin-2 binds to the ␤-subunit and is subsequently internalized, the ␣-subunit is shed from the cell surface and can be detected in the serum as soluble interleukin-2 receptor (sIL-2R). 7, 8 Increased levels of sIL-2R have been detected in patients with high immune activity such as autoimmune diseases, 9 allograft rejection, 10, 11 and severe infection. 12 Therefore in these settings treatment with anti-IL-2 receptor monoclonal antibodies would be of clinical value 5 as animal models have shown. 13, 14 The use of anti-IL-2 receptor monoclonal antibodies has also been reported in the context of aGVHD treatment in animal models 15, 16 as well as humans. 17, 18 In this report we evaluated cytokine levels in 21 patients after allogeneic BMT in order to evaluate an additional parameter which could be helpful in establishing the diagnosis of aGVHD and to discriminate symptoms of aGVHD from those of organ toxicity and infection.
Materials and methods

Patients
Serial evaluations of serum cytokine levels were performed in 21 patients, receiving allogeneic BMT in our center between April 1992 and December 1993. Eighteen of these patients received bone marrow from HLA-matched related donors, two patients received a HLA-matched unrelated donor bone marrow graft, one patient received a related marrow graft with one HLA-mismatch. The median age of the patients was 32 (range 4-53) years. The diagnosis included ALL (n = 7), AML (n = 9), CML (n = 3), severe aplastic anemia (n = 2). Conditioning regimens included busulfan (16 mg/kg of recipient's body weight (BW) ), cyclophosphamide (30 mg/kg BW), etoposide (15-45 mg/kg BW), ATG (30 mg/kg BW) and fractionated TBI (12 Gy). Table 1 shows the different conditioning regimens. Prophylaxis of aGVHD consisted of cyclosporin A starting on day −1 and four injections of methotrexate (day 1, 3, 6 and 11). All patients received G-CSF (5 g/kg BW) starting on day 1 after marrow infusion.
Grading of aGVHD was performed according to the criteria described by Glucksberg et al. 19 Four patients developed no signs of aGVHD, grade I aGVHD was noted in two patients, grade II in eight patients, grade III in six patients and grade IV in one patient. Three groups were established according to the grading of aGVHD: absence of aGVHD, grades I and II, grades III and IV. Treatment of aGVHD consisted of high-dose methylprednisolone, in one case with additional ATG. Body temperature, concentration of serum C-reactive protein levels and organ toxicity were evaluated daily as well as the maximum morphine dose during hospitalization.
Enzyme-linked immunosorbent assay
Evaluation of serum sIL-2R levels was performed serially until day +175 after transplantation and once prior to BMT from 12 patients (UPN 1 to 12 in Table 1 ). The samples were stored at −80°C until measurement. The serum sIL-2R concentration was evaluated using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) with two murine anti-human-sIL-2R antibodies, detecting different epitopes each (Cellfree Interleukin-2 receptor test kit; T Cell Diagnostics, Cambridge, MA, USA). With these antibodies the ␣-subunit of the IL-2 receptor (CD25) is detected. Samples from healthy volunteers were used as the control. Other cytokines such as stem cell factor (SCF, n = 6), interleukin-6 (IL-6, n = 16) and -8 (IL-8, n = 12), granulocyte colony-stimulating factor (G-SCF, n = 5), intercellular adhesion molecule-1 (ICAM-1, n = 21) and soluble tumor necrosis factor-receptor (sTNF-R, n = 20) were also evaluated as described above using commercially available ELISA systems (Cellfree ICAM-1 test kit by T Cell Diagnostics; Quantikine IL-6, Quantikine IL-8 and Quantikine SCF by R&D Systems, Minneapolis, MN, USA and sTNF-R ELISA by Bender MedSystems, Vienna, Austria).
Statistical analysis
Evaluation of significance was performed using nonparametric tests: Mann-Whitney U test, Friedmann test, Spearman rank correlation. A level of P Ͻ 0.05 was considered statistically significant. Week 1 comprises day 1 to day 7, week 2 the days 8 to 14 etc. If not mentioned otherwise data are given as mean and standard error of the mean (s.e.m.).
Results
A significant correlation (r = 0.8, P = 0.008) could be shown between the serum level of sIL-2R and grade of aGVHD as well as the duration of hospitalization (r = 0.8, P = 0.008). No further correlation between sIL-2R serum levels and the day of onset of aGVHD, the number of days with body temperature Ͼ38°C, the peak value of the Creactive protein as well as the age of the patient could be established. No correlation was found between the organ toxicity score or the maximum morphine dose (as an individual though subjective indicator for severity of mucositis) and sIL-2R. Furthermore no significant correlation between sIL-2R serum levels and the day of myeloid or platelet engraftment (sustained absolute neutrophil count Ͼ0.5 × 10 9 /l or platelet count Ͼ20 × 10 9 /l without transfusion respectively) was evaluable. None of the other cytokines evaluated or soluble cytokine receptor polypeptides (SCF, IL-6, IL-8, G-CSF, ICAM-1 and sTNF-R) correlated significantly with the grade of aGVHD. Only IL-6 values showed significant negative correlation with the day of onset of aGVHD (r = −0.77; P = 0.04). Serum TNF levels correlated negatively with the day of engraftment (r = −0.81, P = 0.031). SCF and ICAM-1 serum levels showed no clear pattern during the course of time after transplantation and no definite peak could be found.
As sIL-2R was the only soluble cytokine receptor polypeptide to correlate significantly with the grade of aGVHD, these 12 patients were evaluated in more detail: a significant increase of the sIL-2R concentration was observed in the third week after transplantation (Figure 1 ) with a mean of 4911 U/ml (range 2050 U/ml to 9426 U/ml) as compared to day 0 (mean of 831 U/ml; range 426 U/ml to 1615 U/ml; P = 0.02) and week 6 (mean of 1254 U/ml; range 715 U/ml to 1794 U/ml; P = 0.046). Analyzing the data with regard to aGVHD grading revealed the following pattern: patients without aGVHD showed no peak in the sIL-2R serum level, patients suffering from grade I and II aGVHD had a smaller peak than those with grade III and IV (Figure 2 ). The mean maximum serum levels of sIL-2R in patients without aGVHD (n = 3) was 1167 U/ml (s.e.m. 64 U/ml), in patients with grade I and II aGVHD (n = 4) 2581 U/ml (s.e.m. 658 U/ml) and in patients with grade III and IV (n = 5) 6404 U/ml (s.e.m. 2052 U/ml). The difference between no aGVHD and grade I + II or grade III + IV was significant (P = 0.033 and 0.025, respectively). This significance is also found if the patients are grouped according to the necessity for aGVHD therapy, thus in grade 0 + I aGVHD and grade II to IV aGVHD (P = 0.01). Not surprisingly, patients without aGVHD had a significantly shorter duration of hospitalization than those with aGVHD, irrespec- tive of the grade of aGVHD (26 Ϯ 4 days vs 41 Ϯ 4 days).
There was no significant difference in the day of onset of aGVHD, the number of days with body temperature Ͼ38°C, the peak value of the C-reactive protein, the organ toxicity score, the maximum morphine dose as well as the age of the patient between patients with no aGVHD, grades I + II as well as grades III + IV. The median onset of aGVHD was on day 14 (range 8-17 days), the end of week 2. Therefore the rise of sIL-2R serum levels (peak on week 3) can be observed parallel to or very shortly after the onset of aGVHD. Analyzing the day of myeloid engraftment (sustained absolute neutrophil count Ͼ0.5 × 10 9 /l) in the 12 patients in which sIL-2R serum values were established interestingly revealed that patients with no aGVHD engrafted earlier than those with aGVHD (P = 0.036): day 10 vs day 18 (Ϯ1 each). Analyzing all 21 patients tested showed the same result: patients with no aGVHD engrafted on day 11 (Ϯ1), those with grade I and II aGVHD on day 17 (Ϯ1) and those with grade III and IV aGVHD on day 19 (Ϯ2). The difference between no aGVHD and grades I and II or III and IV respectively is significant (P = 0.034 and P = 0.025).
Discussion
In this study we evaluated serum levels of sIL-2R, sTNF-R, SCF, IL-6, IL-8, G-SCF and ICAM-1 in patients after allogeneic BMT in order to find an additional parameter that could be helpful to discriminate between the symptoms common to aGVHD, organ toxicity or infection, such as skin rash, diarrhea or elevated liver enzymes and bilirubin. We could demonstrate a clear correlation between sIL-2R serum levels and the severity of aGVHD. No correlation was found between organ toxicity, maximum level of Creactive protein or the number of days with body temperature Ͼ38°C and sIL-2R serum levels. Other cytokines tested showed no relation between sIL-2R and aGVHD.
Highest peak levels of sIL-2R were found in patients suffering from grade III + IV aGVHD; patients with grade I + II had less elevated serum levels. Patients without aGVHD had no peak in sIL-2R serum levels after BMT. Our results are supported by the data of Siegert et al, 20 Miyamoto et al 21 and even by Engelhard et al, 22 using T cell-depleted bone marrow. They found a clear correlation between peak sIL-2R levels and severity of aGVHD. Discrepancies between absolute values reported are probably due to different laboratory techniques. Miyamoto et al 21 do not provide additional analysis of C-reactive protein, fever or organ toxicity. Siegert et al 20 found an influence of the duration of fever on the course of the sIL-2R concentration and its peak after BMT, but they also do not provide information on C-reactive protein levels or toxicity. To analyze the influence of other parameters than aGVHD on the serum concentration of sIL-2R, we evaluated the concentration of C-reactive protein in the serum, the number of days with fever (Ͼ38°C) and the organ toxicity. The maximum dosage of morphine as an indicator (though subjective) for mucositis was also included. We could not establish any correlation of these parameters with sIL-2R serum levels. Additionally, the patient's age and the day of myeloid or platelet engraftment had no influence on the sIL-2R level. Engelhard et al 22 reported elevated sIL-2R levels in patients with cytomegalovirus (CMV) infection with or without aGVHD but also in patients with aGVHD alone, correlating with the severity of aGVHD. He found no statistically significant difference in sIL-2R serum levels between patients with aGVHD alone, CMV infection alone or CMV infection and aGVHD together. Siegert et al 20 reported one patient suffering from CMV infection together with grade III aGVHD. The sIL-2R levels in this patient were in the upper range of the values determined. Miyamoto et al 21 reported two infections with adenovirus type 11 32 in two patients without aGVHD, but sIL-2R levels of these patients were not comparable to those seen in aGVHD. In our group of patients one patient was suffering from CMV infection, his peak sIL-2R levels were within the upper range (data not shown), none of our patients developed documented bacterial infections. We agree with Miyamoto et al 21 that the presence of infections should not prevent the use and interpretation of sIL-2R levels as indicator for aGVHD. However, one should be aware of possible increases of sIL-2R levels mainly in CMV infections.
Soluble cytokine receptor polypeptides other than sIL-2R, as well as some cytokines, have been proposed as markers for aGVHD, most often TNF␣, 21, 23 but some authors state that evaluation of sIL-2R would be advantageous to serum TNF␣, as sIL-2R provides a better correlation with the severity of GVHD. 21 Toren et al 24 reported elevated levels of soluble interleukin-6 receptor (sIL-6R) serum levels in patients following BMT without a correlation between sIL-6R levels and the severity of aGVHD. Several groups have used monoclonal antibodies against sIL-2R to prevent disadvantageous immune reactions in animal models. 13, 14 Some trials also used anti-sIL-2R monoclonal antibody for the prophylaxis 25 and treatment of GVHD 17, 18 with promising results.
Increase of sIL-2R levels does not reflect the onset of hematopoietic engraftment, since patients without aGVHD showed no peaks of serum levels after BMT. We suppose that the increase in sIL-2R serum levels reflects the immunoactivity of T lymphocytes, activated by the immunodisparity between host and donor and is therefore an indicator of aGVHD. However, one should be careful in interpreting sIL-2R levels in the presence of CMV infection. In patients presenting with symptoms that could be due to either aGVHD or organ toxicity as well as infections, serial evaluation of sIL-2R can therefore be helpful in establishing and supporting the diagnosis of aGVHD and in starting adequate treatment as early as possible, especially in patients with late engraftment.
